ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Clinical impact of PSMA PET/CT on the management of biochemical recurrence in prostate cancer.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGa-68 prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) improves lesion detection in patients with biochemical recurrence (BCR) of prostate cancer. However, real-world evidence linking imaging-driven management changes to early biochemical outcomes remains limited, particularly in Korean populations. This study aimed to evaluate the impact of Ga-68 PSMA PET/CT on clinical management and its association with early biochemical response.
methodsThis study included retrospectively registered 75 patients who underwent Ga-68 PSMA PET/CT for suspected BCR after radical prostatectomy between September 2022 and February 2024. Intended management at referral and final management after PET were compared. Biochemical outcomes were assessed based on follow-up prostate-specific antigen (PSA) levels.
resultsSeventy-five patients were analyzed (median age, 71 years; median PSA level, 0.30 ng/mL). PSMA PET/CT demonstrated positive findings in 28 patients (37.3%), including equivocal finding. Overall, intended management was changed in 19 patients (25.3%) following PET/CT. At after 2 years of follow-up, 49 patients achieved PSA ≤ 0.20 ng/mL, and 36 achieved PSA ≤ 0.03 ng/mL.
conclusionsIn prostate cancer patients with suspected BCR, Ga-68 PSMA PET/CT led to clinically meaningful changes in management and influenced treatment selection in a Korean cohort. Larger prospective studies are warranted to further define its incremental clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.